{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-063974","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.208290+00:00","generated_at":"2026-05-16T01:13:35.881146+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ORIC reports Q4 2025 cash of $392.3M; positive Phase 1b data for rinzimetostat and enozertinib","bullets":["Cash and investments $392.3M at Dec 31, 2025; proforma $412.3M after $20M ATM in 2026; runway into 2H 2028.","Raised $264M from healthcare specialist funds in 2025 via private placement ($124.4M) and ATM ($117.6M).","R&D expenses Q4 2025 $25.9M (down 19% YoY); full year 2025 $109.8M (down 4% YoY).","Rinzimetostat Phase 1b: 55% PSA50, 20% PSA90, 76% ctDNA reduction; favorable safety vs competitors.","Enozertinib Phase 1b: 67% ORR in 1L EGFR exon20, 80% ORR in 1L EGFR PACC; 100% intracranial ORR."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-063974","json":"https://secwatch.observer/filing/0001193125-26-063974.json","markdown":"https://secwatch.observer/filing/0001193125-26-063974.md","text":"https://secwatch.observer/filing/0001193125-26-063974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526063974/0001193125-26-063974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526063974/oric-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:13:35.881146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}